Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports from Army advance knowledge in cancer vaccines
June 10th, 2009
"HER2/neu, a source of immunogenic peptides, is expressed in > 75% of breast cancer patients. We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression," scientists writing in the journal Clinical Cancer Research report. "Vaccine response based on HER2/neu expression level was analyzed. Patients were stratified by HER2/neu expression. Low expressors (n = 100) were defined as HER2/neu immunohistochemistry (IHC) 1(+) to 2(+) or fluorescence in situ hybridization <2.0. Overexpressors (n = 51) were defined as IHC 3(+) or fluorescence in situ hybridization >= 2.0. Additional...
Source: Vaccine Weekly (2009-06-10)
|
